NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS conditions. There is an emerging consensus that neuroinflammation plays a significant role in CNS disease. NeuroTherapia is developing therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/06/24 | $12,300,000 | Series B |
Alzheimer's Drug Discovery Foundation Brain Trust Accelerator Fund Cleveland Clinic  CRUINT Dolby Family Ventures Foundation for a Better World | undisclosed |
